



EXECUTE SUCCESSSM

Regulatory Circular RG13-130

Date: October 16, 2013

To: Trading Permit Holders

From: Market Operations Department

RE: Restrictions on Transactions in Savient Pharmaceuticals, Inc (SVNT)

Effective October 17, 2013, Savient Pharmaceuticals, Inc (SVNT) will be delisted from the NASDAQ Global Market and will move its listing to the Other-OTC market under the symbol SVNTQ. Therefore, trading in SVNTQ options will be subject to restrictions.

Trading on CBOE in existing series of SVNTQ options will be subject to the following restrictions. Only closing transactions may be affected in any series of SVNTQ options except for (i) opening transactions by Market-Makers executed to accommodate closing transactions of other market participants and (ii) opening transactions by CBOE TPH organizations to facilitate the closing transactions of public customers executed as crosses pursuant to and in accordance with CBOE Rule 6.74(b) or (d).

The execution of opening transactions in SVNTQ options, except as permitted above, and/or the misrepresentation as to whether an order is opening or closing, will constitute a violation of CBOE rules, and may result in disciplinary action. TPH organizations should ensure that they have appropriate procedures in place to prevent their customers from entering opening orders in this restricted option class. In addition, transactions in contravention of this restriction may be subject to nullification pursuant to Exchange Rule 6.25.

There are no restrictions in place with respect to the exercise of SVNTQ options.

Any questions regarding this circular may be directed to Kerry Winters at helpdesk@cboe.com and (312) 786-7312 or the Regulatory Interpretations and Guidance team at RegInterps@cboe.com and by telephone at (312) 786-8141.

CBOE restricted class memos can be accessed from CBOE.org at the following web address: <http://www.cboe.org/Restrictions>